Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial.

Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial. Abstract Text:

Jinlin Hou,You-Kuan Yin,Daozhen Xu,Deming Tan,Junqi Niu,Xiaqiu Zhou,Yuming Wang,Limin Zhu,Yongwen He,Hong Ren,Mobin Wan,Chengwei Chen,Shanming Wu,Yagang Chen,Jiazhang Xu,Qinhuan Wang,Lai Wei,George Chao,Barbara Fielman Constance,George Harb,Nathaniel A Brown,Jidong Jia,

Chronic hepatitis B and its life-threatening sequelae are highly prevalent in China. There is a need for effective new therapies to suppress hepatitis B virus (HBV) replication and ameliorate liver disease. In this study, we compared the efficacy of telbivudine, a nucleoside analogue, with lamivudine in Chinese patients. In this phase III, double-blind, multicenter trial conducted in China, 332 patients with compensated hepatitis B e antigen (HBeAg)-positive or HBeAg-negative chronic hepatitis B were randomly assigned to treatment with 600 mg of telbivudine or 100 mg of lamivudine daily for 104 weeks. The primary efficacy endpoint was reduction in serum HBV DNA levels at week 52 of treatment. Secondary endpoints included clearance of HBV DNA to undetectable levels, HBeAg loss and seroconversion, therapeutic response, and alanine aminotransferase (ALT) normalization. Viral resistance and safety were assessed. At week 52, among 290 HBeAg-positive patients, mean reductions of serum HBV DNA were significantly greater in telbivudine recipients than lamivudine recipients (6.3 log(10) versus 5.5 log(10), P < 0.001), and HBV DNA was polymerase chain reaction-negative in significantly more telbivudine recipients than lamivudine recipients (67% versus 38%, P < 0.001). ALT normalization (87% versus 75%, P = 0.007), therapeutic response (85% versus 62%, P = 0.001), and HBeAg loss (31% versus 20%, P = 0.047) were also significantly more common in the telbivudine group. Treatment effects showed similar patterns in the smaller HBeAg-negative group (n = 42). Viral resistance in telbivudine recipients was approximately half that observed with lamivudine; however, this difference was not statistically significant. Clinical adverse events were similar in the two treatment groups. CONCLUSION: In Chinese patients with chronic hepatitis B, telbivudine treatment for 52 weeks provided greater antiviral and clinical efficacy than lamivudine, with less resistance.

Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial. Publishing Authors By Initials

J Hou,YK Yin,D Xu,D Tan,J Niu,X Zhou,Y Wang,L Zhu,Y He,H Ren,M Wan,C Chen,S Wu,Y Chen,J Xu,Q Wang,L Wei,G Chao,BF Constance,G Harb,NA Brown,J Jia,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Hepatology (Baltimore, Md.)

VOLUME: 47

Page Numbers: 447-54

Journal Abbreviation: Hepatology

ISSN: 1527-3350

DAY: 5

MONTH: Feb

YEAR: 2008

Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8302946

Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial.

AFFILIATION: Nanfang Hospital, Guangzhou, China.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Hepatology

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER: NCT00131742

Number Hits: 0

Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial Related Publications

• Changes in aroma volatile compounds and ethylene production during "Hujingmilu" peach (Prunus persica L.) fruit development.
• The role of B7 molecules in T cell anergy.
• [A study on acquired acid resistance of enamel and dentine irradiated by Er, Cr: YSGG laser in vitro]
• [A study on noise controlling of the electromagnetic valve in external counterpulsation devices]
• [Adjustment of lipiodol dose according to tumor blood supply during the transcatheter arterial chemoembolization for large hepatic carcinoma by mulitdetector helical CT]
• [Analysis of gas absorption coefficient at various pressures]
• [Assessment of genetic diversity of Rehmannia glutinosa germplasm detected by RAPDs and ISSRs]
• [Burn clinical research--a field deserves emphasizing]
• [Changes of subsets of DC1 in the bone marrow of severe aplastic anemia patients.]
• [Comparison of methods to construct a full-length cDNA library]
• [Determination of calcium in brains of rat by ICP-AES]
• [Development of biodegradable and bioabsorbable bone-repaired materials]
• [Effect of survivin antisense oligodeoxynuclecotide on carcinoma of larynx in vivo and in vitro]
• [Evaluation of early and rapid etiological diagnosis of measles by detection of measles virus RNA using nested RT-PCR]
• [Experimental study on the inhibition of fibroblast contraction by alpha smooth muscle actin fusion protein]
• [Immune complex induced rat liver fibrosis model by intraperitoneal injection of human serum albumin]
• [Increased lectin-like oxidized low density lipoprotein receptor-1 expression in the autologous vein grafts and vein graft atherosclerosis]
• [Inhibitory kinetic-synchronous fluorimetric determination of trace aniline]
• [Isolation and prelimary characterization of a kind of rat liver potential progenitor cells small round hepatic cells]
• [Joint statement of establishing Chinese Clinical Trial Registration and Publishing system]
• [Monomer drug's special effect and application of western medicine based on the theory of traditional Chinese medicine]
• [Nomenclature and abbreviation in nitric oxide research]
• [Properties and applications of restricted access stationary phases]
• [Protective effect of vitamin C on protein activity in plasma during virus inactivation]
• [Spectroscopic evaluation of time-resolved fluoroimmunoassay]
• [Study of the dento-facial features in children of Han nationality with normal occlusion in Shandong district]
• [Supratentorial cavernous angiomas in children]
• [The clinical evaluation of patients with pituitary adenomas undergone transsphenoidal microsurgery]
• [The role of MPO mRNA, IgH mRNA and CD3epsilon mRNA expressions in classification of acute leukemias]
• [Vector-mediated HER-2 RNA interference against HER-2-positive breast cancer]